CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase
Journal of Cystic Fibrosis · 2026
DOI: 10.1016/j.jcf.2025.11.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Nazanin Abolhassani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Pregnancy Complications, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have transformed the management of cystic fibrosis (CF), but evidence on their safety during pregnancy remains limited and pregnancy-related adverse drug reactions (ADRs) are not well characterized. METHODS: We analyzed VigiBase, the World Health Organization global pharmacovigilance database of individual case safety reports (ICSRs), to identify signals of disproportionate reporting (SDRs) for pregnancy-related ADRs associated with elexacaftor, ivacaftor, tezacaftor and lumacaftor, reported until 15 December 2024. RESULTS: Of 1035 pregnancy-related ICSRs with CFTR modulators, 280 met inclusion criteria. Two SDRs were identified: spontaneous abortion (n = 96 events, reporting odds ratio [ROR] 2.43; 95% confidence interval [CI] 1.99-2.97) and pre-eclampsia (n = 17 events, ROR 4.29; 95% CI 2.66-6.92). Reported birth defects were heterogeneous, with no recurring patterns. There was no SDR for prematurity. These findings align with recent observational studies and preclinical data indicating no teratogenic effects of CFTR modulators. CONCLUSION: CFTR modulators were not associated with the reporting of consistent patterns of congenital anomalies or prematurity in this large pharmacovigilance analysis. SDRs for spontaneous abortion and pre-eclampsia should be interpreted cautiously given the limitations inherent to the used study design and require confirmation in prospective pregnancy registries and controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- Swiss Teratogen Information Service and Clinical Pharmacology Service, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano,…
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; Service of Pharmacy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
- Swiss Teratogen Information Service and Clinical Pharmacology Service, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland. Electronic address: ursula.winterfeld@chuv.ch.
Zitieren
APA
Abolhassani, N., Dao, K., Noseda, R., Bedussi, F., Ceschi, A., Panchaud, A., & Winterfeld, U. (2026). CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.11.007
Vancouver
Abolhassani N, Dao K, Noseda R, Bedussi F, Ceschi A, Panchaud A, et al. CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.11.007
BibTeX
@article{Abolhassani2026,
author = {Abolhassani, Nazanin and Dao, Kim and Noseda, Roberta and Bedussi, Francesca and Ceschi, Alessandro and Panchaud, Alice and Winterfeld, Ursula},
title = {CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase},
journal = {Journal of Cystic Fibrosis},
year = {2026},
doi = {10.1016/j.jcf.2025.11.007}
}
EUVIMED